The JAK2 (Janus Kinase 2) is becoming very relevant in ongoing cancer studies, mainly in the area of myeloproliferative disorders (MPD’s). These disorders can be classified as diseases where the bone marrow produces excess cells. Coincidentally, many MPD’s are related and often evolve into cancers such as acute myeloid leukemia. Polycythemia vera (PV), one of the more common MPD’s, is a brand of MPD in which the bone marrow produces too many red blood cells.
Amazingly, recent research has shown a mutation in the JAK2, ties all of the above information together. Multiple research facilities recently observed a mutation recognized now as JAK2 V617F, more commonly called the JAK2+ mutation. Many researchers are in agreement that a major breakthrough in MPD therapeutics can be discovered by further understanding this JAK2+ mutation.
Currently, JAK2+ inhibitors are being tested in vitro and through clinical trials. By providing clients with specimens known to be JAK2+ we feel we are fueling advances in MPD’s and PV studies. If you have any questions or comments about our JAK2+ samples please feel to leave a comment or fill out the form to the left
